Climb Bio Inc (CLYM)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
Research Workspace
Put CLYM beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisThis stock is volatile — it swings about 2% on a typical day and fell roughly 51% in its worst 12-month stretch.
View RiskClimb Bio's clinical pipeline must keep advancing to justify the current price. The company beat its Q2 FY2026 earnings estimate by 18.2%. Recent Phase 2 data supports the development of its lead assets. We cannot anchor a clean multiple because the company is unprofitable. The price is roughly in line with the growth we forecast. A 39% probability of a next-quarter miss is a specific risk. Peer multiples imply a price about 63% above where it trades. Our standing thesis is intact, but this read is provisional.
Trailing returns as of 2026-11-04. CLYM is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering CLYM (as of Nov 2026).
Based on 9 Wall Street analysts offering 12-month price targets for CLYM in the last 4 months.
Continue this research
Compare CLYM with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CLYM Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put CLYM next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance budoprutug clinical development
Official presentation of key clinical data for lead asset.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $9.33
The last 12 months of price, then the range of analyst 12-month targets from today’s $9.33.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.

Advances: Advance CLYM116 development and data presentation
Phase 2 data presentation supports CLYM116 development.

Advances: Advance CLYM116 development and data presentation
Price target increase reflects positive sentiment on drug data.

Analyst target increase supports positive outlook on trial data.

Advances: Advance budoprutug clinical development
Advancing Phase 2 trial supports clinical development objective.

Threatens: Advance CLYM116 development
Stock dip indicates concerns over CLYM116 safety data.
Advances: Advance CLYM116 development
Positive rating on IgAN opportunity supports CLYM116 development.